Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.
2.

A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9.

Holla ØL, Strøm TB, Cameron J, Berge KE, Leren TP.

Mol Genet Metab. 2010 Feb;99(2):149-56. doi: 10.1016/j.ymgme.2009.09.012. Epub 2009 Sep 27.

PMID:
19828345
3.

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor.

Zhang DW, Garuti R, Tang WJ, Cohen JC, Hobbs HH.

Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13045-50. doi: 10.1073/pnas.0806312105. Epub 2008 Aug 27.

4.

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis.

Qian YW, Schmidt RJ, Zhang Y, Chu S, Lin A, Wang H, Wang X, Beyer TP, Bensch WR, Li W, Ehsani ME, Lu D, Konrad RJ, Eacho PI, Moller DE, Karathanasis SK, Cao G.

J Lipid Res. 2007 Jul;48(7):1488-98. Epub 2007 Apr 20.

5.

Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.

Cameron J, Holla ØL, Ranheim T, Kulseth MA, Berge KE, Leren TP.

Hum Mol Genet. 2006 May 1;15(9):1551-8. Epub 2006 Mar 28.

PMID:
16571601
6.

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.

Ferri N, Tibolla G, Pirillo A, Cipollone F, Mezzetti A, Pacia S, Corsini A, Catapano AL.

Atherosclerosis. 2012 Feb;220(2):381-6. doi: 10.1016/j.atherosclerosis.2011.11.026. Epub 2011 Nov 25.

PMID:
22176652
7.

Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation.

Fisher TS, Lo Surdo P, Pandit S, Mattu M, Santoro JC, Wisniewski D, Cummings RT, Calzetta A, Cubbon RM, Fischer PA, Tarachandani A, De Francesco R, Wright SD, Sparrow CP, Carfi A, Sitlani A.

J Biol Chem. 2007 Jul 13;282(28):20502-12. Epub 2007 May 10.

8.

Low-density lipoprotein receptor activity in Epstein-Barr virus-transformed lymphocytes from heterozygotes for the D374Y mutation in the PCSK9 gene.

Holla ØL, Cameron J, Berge KE, Kulseth MA, Ranheim T, Leren TP.

Scand J Clin Lab Invest. 2006;66(4):317-28.

PMID:
16777760
9.

Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells.

Fasano T, Sun XM, Patel DD, Soutar AK.

Atherosclerosis. 2009 Mar;203(1):166-71. doi: 10.1016/j.atherosclerosis.2008.10.027. Epub 2008 Nov 6.

PMID:
19081568
10.

PCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum.

Strøm TB, Tveten K, Leren TP.

Biochem J. 2014 Jan 1;457(1):99-105. doi: 10.1042/BJ20130930.

PMID:
24144304
11.

MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression.

Yan H, Ma YL, Gui YZ, Wang SM, Wang XB, Gao F, Wang YP.

Acta Pharmacol Sin. 2014 Aug;35(8):994-1004. doi: 10.1038/aps.2014.52. Epub 2014 Jul 21.

12.

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts.

Nguyen MA, Kosenko T, Lagace TA.

J Lipid Res. 2014 Feb;55(2):266-75. doi: 10.1194/jlr.M044156. Epub 2013 Dec 2.

13.

Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor.

Duff CJ, Scott MJ, Kirby IT, Hutchinson SE, Martin SL, Hooper NM.

Biochem J. 2009 May 1;419(3):577-84. doi: 10.1042/BJ20082407.

14.

Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells.

McNutt MC, Kwon HJ, Chen C, Chen JR, Horton JD, Lagace TA.

J Biol Chem. 2009 Apr 17;284(16):10561-70. doi: 10.1074/jbc.M808802200. Epub 2009 Feb 17.

15.

PCSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment.

Tveten K, Strøm TB, Berge KE, Leren TP.

J Lipid Res. 2013 Jun;54(6):1560-6. doi: 10.1194/jlr.M034371. Epub 2013 Mar 18.

16.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).

Canuel M, Sun X, Asselin MC, Paramithiotis E, Prat A, Seidah NG.

PLoS One. 2013 May 13;8(5):e64145. doi: 10.1371/journal.pone.0064145. Print 2013.

17.

β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.

Starr AE, Lemieux V, Noad J, Moore JI, Dewpura T, Raymond A, Chrétien M, Figeys D, Mayne J.

FEBS J. 2015 Jul;282(14):2682-96. doi: 10.1111/febs.13309. Epub 2015 May 18.

18.

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.

Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC, Hobbs HH.

J Biol Chem. 2007 Jun 22;282(25):18602-12. Epub 2007 Apr 23.

19.

Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.

Kosenko T, Golder M, Leblond G, Weng W, Lagace TA.

J Biol Chem. 2013 Mar 22;288(12):8279-88. doi: 10.1074/jbc.M112.421370. Epub 2013 Feb 11.

20.

A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.

Ni YG, Condra JH, Orsatti L, Shen X, Di Marco S, Pandit S, Bottomley MJ, Ruggeri L, Cummings RT, Cubbon RM, Santoro JC, Ehrhardt A, Lewis D, Fisher TS, Ha S, Njimoluh L, Wood DD, Hammond HA, Wisniewski D, Volpari C, Noto A, Lo Surdo P, Hubbard B, Carfí A, Sitlani A.

J Biol Chem. 2010 Apr 23;285(17):12882-91. doi: 10.1074/jbc.M110.113035. Epub 2010 Feb 19.

Supplemental Content

Support Center